Intravitreal Bevacizumab Versus Combined Intravitreal Triamcinolone Acetonide and Bevacizumab for Pseudophakic Diabetic Macular Edema

Saturday, April 18, 2015: 3:36 PM
Room 1A (San Diego Convention Center)
Ayman Lotfy, MD
Ahmed Samir, MD
Ayman M. Elsayed, MD, FRCS

To assess the efficacy of the combined intravitreal (IVT) injection of Triamcinolone Acetonide (TA) and bevacizumab as compared to repeated intravitreal bevacizumab for the treatment of cystoid diabetic macular edema in pseudophakic eyes.

This prospective interventional comparative randomized trial included fifty pseudophakic patients presenting cystoids macular edema. The same patients’ one eye was assigned randomly to combined 4 mg IVT injection of TA and 1.25mg bevacizumab and the fellow eye was then treated with three consecutive IVT injection of 1.25mg bevacizumab.  Max macular thickness and IOP were measured before and after one and three months of treatment.

Max macular thickness of the eyes treated was significantly reduced with insignificant difference between the two groups. IOP of the eyes treated with IVT injection significantly increased.

The repeated bevacizumab intravitreal injections can be considered a valid alternative to the combined intravitreal injection with low risk of IOP elevation; however larger and longer multicenter studies are needed.